tesamorelin cycle: Frequently asked questions

Extend the cycle to 16–20 weeks before declaring non-response. Some metabolic phenotypes require longer GH exposure to overcome baseline lipolytic resistance, particularly in models with insulin resistance or elevated cortisol. Verify dosing accuracy, injection technique, and peptide storage conditions. Temperature excursions above 8°C denature the peptide, rendering it inactive. If VAT remains unchanged at week 20 despite confirmed dosing and storage, the subject may have developed early antibody response or possess genetic variants in GHRH receptor expression that blunt responsiveness.

Implement antibody monitoring at weeks 12, 20, and 26, and use antibody-negative status as a continuation criterion. Subjects who remain antibody-negative at week 26 can extend to week 40–52 with acceptable risk, though efficacy plateaus typically occur regardless. Consider dose reduction to 1.5mg daily after week 26 to minimize cumulative antigen exposure while maintaining some degree of GH stimulation. Document all immunogenic events meticulously. Continuous dosing beyond 26 weeks is off-label for most research applications and requires IRB awareness in human studies.

Verify peptide reconstitution and storage protocols first. Tesamorelin must be reconstituted with bacteriostatic water and stored at 2–8°C after mixing. Improper reconstitution is the most common cause of apparent non-response. If reconstitution is confirmed correct, check baseline pituitary function through GH stimulation testing. Some subjects have blunted endogenous GH reserve due to aging, chronic stress, or pituitary pathology, and will show minimal IGF-1 response to GHRH agonists regardless of dose. These subjects may respond better to direct GH administration rather than secretagogues, though that falls outside tesamorelin's mechanism.

Terminate the cycle immediately and implement a 12-week washout to allow antibody clearance. Continuing to dose an antibody-positive subject wastes peptide and accelerates immune memory formation, making future cycles even less effective. After washout, reassess antibody status before initiating a second cycle. If titers remain elevated, the subject is not a candidate for repeat tesamorelin exposure. Alternative growth hormone secretagogues like GHRP 2 or Hexarelin act through different receptor pathways and may bypass the immunogenic response.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed. If more than 12 hours late, skip the missed dose and resume your normal schedule the next morning. Do not double-dose to compensate. Missing 2–3 doses per month does not significantly impact overall cycle efficacy, but inconsistent timing (injecting at different times daily) disrupts circadian synchronisation and reduces peak GH response by 20–30%.

Verify injection timing and fasting state first. Post-meal administration is the most common protocol error. If timing is correct, confirm peptide storage integrity (refrigerated continuously, no temperature excursions). IGF-1 non-responders are rare but documented in clinical literature. Approximately 8% of research subjects show blunted IGF-1 response despite confirmed GHRH administration, likely due to genetic variations in GHRH receptor density or downstream signalling pathway polymorphisms.

Any reconstituted peptide exposed to temperatures above 8°C for more than four hours should be discarded. Tesamorelin's 44-amino-acid structure is particularly vulnerable to thermal denaturation. The peptide unfolds and aggregates at room temperature, losing biological activity while remaining visually unchanged. Injecting degraded peptide won't cause harm but produces zero therapeutic effect. If you're uncertain about storage conditions, prepare a fresh vial rather than risk an ineffective cycle week.